Now ideas for wellness

About Meiji

At a Glance

At a Glance

Get to know Meiji at a glance – from our core business to our most important numbers.

Food

Our Nutrition Initiatives

Our Nutrition Initiatives

Our goal is to improve the lives of people of all ages around the world through nutrition, from infants to older adults, and we are dedicated to achieving this goal.

Pharmaceuticals

R&D

Medical needs are always diversifying – here's how Meiji is responding.

Pipeline

As of February 8, 2024

Human Vaccines

Stage Name Target Disease Notes
Approved (Japan) KD-370 Pentavalent vaccine against diphtheria, tetanus, pertussis, poliovirus, and Haemophilus influenzae type b  
Approved (Japan) ARCT-154 Self-amplifying mRNA vaccine against COVID-19 Partnership: CSL Seqirus (Australia)
Phase Ⅲ (Japan) ARCT-2301 Self-amplifying mRNA vaccine against COVID-19 (Bivalent: Original strain and Omicron strain) Partnership: CSL Seqirus (Australia)
Phase Ⅲ (Japan) KD-414 Inactivated vaccine against COVID-19 (Adults*) Multi-Regional Clinical Trials
* 18-40 years old
Phase Ⅲ (Japan) KD-414 Inactivated vaccine against COVID-19 (Pediatric*) * 6 months - 11 years old
Phase Ⅲ (Japan) KD-414 Inactivated vaccine against COVID-19 (Pediatric*, Omicron strain) * 6 months - 12 years old
Phase Ⅱ (Japan) KD2-396 Hexavalent vaccine against diphtheria, tetanus, pertussis, poliovirus, Haemophilus influenzae type b, and Hepatitis B virus  
Phase Ⅰ (Overseas) KD-382 Quadrivalent vaccine against dengue fever  

Veterinary Drugs

Stage Name Efficacy Classification Notes
Filed (Japan) ME4137 Injectable antibacterial drug for cattle  
Filed (Japan) ME4137 Injectable antibacterial drug for swine  
Filed (Japan) KD-412 Vaccine for cattle Discovered in-house
Filed (Japan) MD-22-3002 Anti-inflammatory drug for cattle, swine and horse  
Under development ME4305 Antibacterial drug for cattle Discovered in-house
Under development MD-22-1001-1 Injectable antibacterial drug for cattle  
Under development ME4406 Feed Additive Discovered in-house